HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport

Sunitinib, a multikinase inhibitor approved for a number of cancer indications has a low response rate. Identifying mechanisms of resistance could lead to rational combination regimens that could improve clinical outcomes. Here we report that resistance to sunitinib therapy was driven by autophagic...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Peihua, Xu, Zhifei, Li, Guanqun, Yan, Hao, Zhu, Yi, Zhu, Hong, Ma, Shenglin, Yang, Bo, He, Qiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper - Translational
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984767/
https://www.ncbi.nlm.nih.gov/pubmed/30205729
http://dx.doi.org/10.1080/15548627.2018.1501134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984767/
https://www.ncbi.nlm.nih.gov/pubmed/30205729
http://dx.doi.org/10.1080/15548627.2018.1501134

Ejemplares similares